Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
45 participants
INTERVENTIONAL
2013-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Relationship between blood TG level and the GCM efficacy will be evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus
NCT01529216
Metformin in the Diastolic Dysfunction of Metabolic Syndrome
NCT02017561
Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus
NCT00829699
Carotid Body Function in Type 2 Diabetes Mellitus
NCT05237076
Development of Minimally Invasive Methodology for Diabetyping to Personalise Treatment to Realise Remission and Reversal of Type 2 Diabetes
NCT06125119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low blood TG patients
subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
DIAMOND System
DIAMOND Implantable Pulse Generator (IPG)
High blood TG patients treated with blood TG lowering therapy
subjects with baseline blood triglyceride level \> 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
DIAMOND System
DIAMOND Implantable Pulse Generator (IPG)
High blood TG patients
subjects with baseline blood triglyceride level \> 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
DIAMOND System
DIAMOND Implantable Pulse Generator (IPG)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DIAMOND System
DIAMOND Implantable Pulse Generator (IPG)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index \> 30 and \< 45 (kg/m2)
* Type 2 diabetes duration of at least 6 months
* Type 2 diabetic subjects treated with oral anti-diabetic agents \[Sulfonylurea, Metformin, thiazolinedione (TZD) or DPP-4 inhibitors\]
* Stable anti-diabetic medications for at least 3 months prior to enrollment, six months for thiazolinedione (TZD)
* The subject has been under routine diabetes care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
* HbA1c 7.3% and ≤ 9.5 % on Visit 1
* Stable HbA1c, defined as no significant change (variation ≤ 0.5%) between a historical value recorded in the subject's medical record within 3 months prior to enrollment and the HbA1c gathered on Visit 1.
* Fasting blood glucose \>120 and \< 350 mg/dl on Visit 1.
* Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
* Stable weight, defined as no significant weight change (variation \<3%) within three months prior to enrollment as documented in the subject's medical record. For the subject treated with thiazolinedione, stable weight within six months.
* If taking theses medication, sable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment
* If subject is under anti-depressant medication the treatment needs to be stable for at least six months prior to enrollment.
* Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the DIAMOND System
* Willingness to perform at least four (3) capillary blood glucose tests per day twice a week for the duration of the study
* Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
* Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
* Able to provide voluntary informed consent
Exclusion Criteria
* Taking GLP-1 agonists or in the last 3 months before the enrollment
* Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic treatment
* Subjects with an EF less than 35% or otherwise indicated for an ICD
* Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics
* Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)
* Prior wound healing problems due to staphylococcus or candida
* Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures
* Use of anti-psychotic medications
* Diagnosed with a eating disorder such as bulimia or binge eating
* Obesity due to an endocrine disorder (e.g. Cushing disease)
* Pregnant or lactating
* Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)
* Any prior bariatric surgery
* Any history of pancreatitis
* Any history of peptic ulcer disease within 5 years of enrollment
* Diagnosed with gastroparesis
* Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.
* Cardiac history that physician feels should exclude the subject from the study.
* Use of another investigator device or agent in the 30 days prior to enrollment
* A history of life-threatening disease within 5 years of enrollment
* Change in diabetic medication from between Visit 1 and Visit 3.
* Any additional condition(s) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MetaCure Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Epworth Research Institute
Richmond, Victoria, , Australia
Tilak Innsbruck
Innsbruck, , Austria
"Attikon" Hospital
Athens, , Greece
"Evgenidio " Hospital
Athens, , Greece
Clinica Pineta Grande
Rome, , Italy
The Università Cattolica del Sacro Cuore
Rome, , Italy
Medical University
Bialystok, , Poland
Medical University
Bydgoszcz, , Poland
"Diabeta-Care"
Lubin, , Poland
Medical University
Szczecin, , Poland
Centre for Postgraduate Medical Education (CMKP)
Warsaw, , Poland
Klinika za digestivnu hirurgiju
Belgrade, , Serbia
Institut za pluće bolesti Vojvodine
Kamenica, , Serbia
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nikolaos Arkadopoulos, Prof.
Role: primary
Dott. Cristiano Giardiello, MD
Role: primary
Maria Górska, MD, PhD
Role: primary
Roman Junik, MD, PhD
Role: primary
Irena Szykowna, MD, PhD
Role: primary
Syrenicz Anhelli, MD, PhD
Role: primary
Wiesław Tarnowski, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MC CP TAN2012-60
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.